Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
In Graves' disease, the presence of excess thyroid hormone induces glomerular hyperfiltration, resulting in an overestimation of the estimated glomerular filtration rate (eGFR) prior to treatment. The restoration of euthyroidism normalizes renal hemodynamics, leading to a decline in eGFR towards the actual level of kidney function. This process can uncover previously unrecognized renal impairment, referred to as "masked chronic kidney disease (CKD)." However, the prevalence, characteristics, and predictors of masked CKD in patients with Graves' disease remain insufficiently understood. Our objectives were to quantify the reduction in eGFR following treatment, assess the prevalence of masked CKD, and identify the determinants of the percentage change in eGFR.
We conducted a retrospective analysis of patients with Graves’ disease who received treatment at our hospital between December 2017 and April 2025. Eligible cases included those who were newly diagnosed or those who relapsed after at least six months off antithyroid drug therapy. Baseline data refer to the most recent values recorded prior to the initiation of therapy, whereas post-treatment data correspond to the initial measurements obtained following the normalization of both FT3 and FT4 levels in the two tests. The eGFR was calculated using the equation provided by the Japanese Society of Nephrology. The primary outcome was the percentage change in the eGFR. Multivariable linear regression analysis included FT4, age, sex, and body mass index (BMI). Masked CKD was defined as a post-treatment eGFR of less than 60 mL/min/1.73m² in patients with a baseline eGFR of 60 mL/min/1.73m² or higher.
A total of 45 patients were included in the final analysis. The study population consisted of 12 men (26.7%) and 33 women (73.3%), with a mean (SD) age of 49.8 (17.2) years. The mean baseline estimated glomerular filtration rate (eGFR) was 148.16 (56.84) mL/min/1.73m², indicating glomerular hyperfiltration. Following treatment, the eGFR significantly decreased to 98.21 (28.47) mL/min/1.73m² (p < 0.001), representing a mean reduction of −30.5%. Masked CKD was identified in 4 patients (8.9%) . In the univariable analyses, both FT3 and FT4 levels were significantly correlated with the % change in eGFR. Mean baseline FT4 levels were 2.57 (0.8) ng/dL. After treatment, FT4 levels were within the normal range in all patients. In the multivariable analysis, higher baseline FT4 was significantly associated with a greater reduction in eGFR (% change), with −6.17 % per 1 ng/dL increase in FT4 (p = 0.016). Subgroup analysis showed modification by body composition: in patients with BMI > 22 kg/m², FT4 remained significant (p = 0.028), but not in those with BMI ≤ 22 kg/m².
In Graves' disease, thyroid hormone–driven hyperfiltration overestimates renal function, and treatment unmasks CKD in 8.9% of patients, with FT4 predicting the decline. Clinicians should interpret elevated eGFR cautiously in thyrotoxic patients and monitor those with significant post-treatment reductions closely.
